Abbott’s Compounding Pharmacy voluntarily recalls sterile products due to lack of sterility assurance.
On Jan. 16, 2016, Abbott’s Compounding Pharmacy announced it was voluntarily recalling all unexpired lots of human and animal sterile compounded products including injectable medications, sterile solutions, eye drops, and eye ointments. The recall is in response to a concern of a lack of sterility assurance after a series of onsite FDA inspections. The recalled products were distributed in California.
The recall is cautionary and the company has not received any reports of adverse events regarding the recalled products as of Jan. 16, 2016. However, because microbial contamination could cause serious effects, the company is advising customers to stop using the products immediately and contact their healthcare provider if they experience problems related to the use of the products.
Source: FDA
FDA Reopens Comment Period on HCP Immunogenicity Risk of Follow-on Recombinant Peptides
January 2nd 2025FDA is reopening the comment period for the Federal Register Notice, “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments”, until March 3, 2025.